DEDICATED TO SAVING LIVES
BY TRANSFORMING AT-HOME
CANCER DETECTION

Early identification of Cancer saves lives.

To be effective, cancer detection needs to be simple, readily available, and affordable.

We develop innovative products that quickly and reliably identify the early onset of several leading deadly conditions – such as colorectal (“CRC”) and pancreatic cancer.

Our goal is to place effective solutions where they need to be… In your hands.

Mainz BioMed (NASDAQ: MYNZ) – was founded in Germany and is becoming a leading global provider of easy-to-use diagnostic solutions for patients and healthcare providers everywhere.

OUR COMPANY

OUR BUSINESS

OUR SOLUTION

LATEST NEWS

  • All
  • Corporate News
  • Media
All
  • All
  • Corporate News
  • Media
Corporate News

Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test

Read More
Corporate News

Mainz Biomed Provides Half Year 2024 Corporate Update

Read More
Corporate News

Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024

Read More